PNV 3.57% $2.61 polynovo limited

The Clinicians Speak, page-550

  1. 1,204 Posts.
    lightbulb Created with Sketch. 214
    In last years annual report they said they were working on 4 prototypes. In the 2023 half year they said:
    PolyNovo has expanded its approachto hernia and is developing targetedsolutions to a range of herniarepair options from simple inguinalto ventral hernia and complexabdominal wall reconstruction.
    and
    Plastics and ReconstructiveDevice ProductsPolyNovo previously announced thatit has taken the breast developmentprogram in-house. We envisage thisprogram will leverage the experienceand processes developed for the herniadevices. The hernia product developmentmodels serve as effective building blocksfor other tissue reinforcement productsin breast, orthopaedics, and otherapplications. We anticipate thatmanufacturing processes, technologyand equipment will be shared acrossa range of new products.

    Given its a building block for a number of new products I think it would be fairly high priority.
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
(20min delay)
Last
$2.61
Change
0.090(3.57%)
Mkt cap ! $1.801B
Open High Low Value Volume
$2.59 $2.66 $2.58 $3.183M 1.217M

Buyers (Bids)

No. Vol. Price($)
2 19229 $2.61
 

Sellers (Offers)

Price($) Vol. No.
$2.62 3084 2
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
PNV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.